Alethea Capital Management, LLC Abb Vie Inc. Transaction History

Alethea Capital Management, LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$154.79 - $180.76 $440,067 - $513,900	2,843 New	2,843 $487,000
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $463,557 - $536,635	3,470 New	3,470 $517,000
Q1 2023 May 15, 2023	BUY	$144.61 - $166.54 $576,993 - $664,494	3,990 New	3,990 $635,000
Q4 2021 Feb 14, 2022	SELL	$107.43 - $135.93 $888,446 - $1.12 Million	-8,270 Closed	0 $0
Q3 2021 Oct 27, 2021	BUY	$106.4 - $120.78 $223,546 - $253,758	2,101 Added 34.06%	8,270 $892,000
Q2 2021 Aug 16, 2021	BUY	$105.21 - $117.21 $649,040 - $723,068	6,169 New	6,169 $695,000
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $1.26 Million - $1.39 Million	-12,338 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $993,085 - $1.34 Million	12,338 New	12,338 $1.32 Million
Q3 2020 Nov 16, 2020	SELL	$85.91 - $100.83 $799,908 - $938,828	-9,311 Closed	0 $0
Q2 2020 Aug 11, 2020	SELL	$73.37 - $98.18 $31,475 - $42,119	-429 Reduced 4.4%	9,311 $914,000
Q1 2020 May 11, 2020	BUY	$64.5 - $97.79 $628,230 - $952,474	9,740 New	9,740 $742,000
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $296,446 - $356,414	-4,707 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$65.7 - $83.98 $309,249 - $395,293	4,707 New	4,707 $342,000
Q3 2018 Oct 29, 2018	SELL	$88.91 - $98.84 $452,107 - $502,601	-5,085 Closed	0 $0
Q2 2018 Jul 17, 2018	SELL	$89.78 - $106.23 $620,738 - $734,474	-6,914 Reduced 57.62%	5,085 $471,000
Q1 2018 Apr 18, 2018	BUY	$92.01 - $123.21 $367,947 - $492,716	3,999 Added 49.99%	11,999 $1.14 Million
Q3 2017 Nov 02, 2017	BUY	$69.85 - $89.22 $558,800 - $713,760	8,000	8,000 $711,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Alethea Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Alethea Capital Management, LLC with notifications on news.